Debra Stephanie Barker
Director/Board Member at BERGENBIO ASA
Net worth: 36 120 $ as of 2024-04-29
Profile
Debra Stephanie Barker is currently serving as a Non-Executive Director at CureVac SE.
She also holds the position of Senior Independent Director at Destiny Pharma Plc, Non-Executive Director at BerGenBio ASA, Senior Independent Non-Executive Director at Arix Bioscience Plc, Director at Hutman Diagnostics AG, Senior Independent Director at Arix Bioscience, and Member-Supervisory Board at CureVac NV.
In her former roles, Dr. Barker worked as the Global Head-Medical Affairs at Novartis AG and as the Chief Medical & Development Officer at Spexis Ltd.
from 2017 to 2018.
Dr. Barker completed her graduate degree at King's College London and obtained a doctorate degree from Queens' College Cambridge.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
DESTINY PHARMA PLC
0.09% | 2023-05-24 | 88,461 ( 0.09% ) | 19 661 $ | 2024-04-29 |
CUREVAC N.V.
0.00% | 2024-03-14 | 7,125 ( 0.00% ) | 16 459 $ | 2024-04-29 |
Debra Stephanie Barker active positions
| Companies | Position | Start |
|---|---|---|
| BERGENBIO ASA | Director/Board Member | 2019-03-12 |
| DESTINY PHARMA PLC | Director/Board Member | 2019-12-31 |
| CUREVAC N.V. | Director/Board Member | 2022-06-21 |
| ARIX BIOSCIENCE PLC | Director/Board Member | 2022-08-09 |
Hutman Diagnostics AG
 Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Director/Board Member | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Director/Board Member | - |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Director/Board Member | 2022-07-31 |
Former positions of Debra Stephanie Barker
| Companies | Position | End |
|---|---|---|
| SPEXIS AG | Chief Tech/Sci/R&D Officer | 2018-12-30 |
| NOVARTIS AG | Corporate Officer/Principal | - |
Training of Debra Stephanie Barker
| Queens' College Cambridge | Doctorate Degree |
| King's College London | Graduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| SPEXIS AG | Health Technology |
| NOVARTIS AG | Health Technology |
| BERGENBIO ASA | Health Technology |
| DESTINY PHARMA PLC | Health Technology |
| CUREVAC N.V. | Health Technology |
| ARIX BIOSCIENCE PLC | Finance |
| Private companies | 3 |
|---|---|
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Health Technology |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Finance |
- Stock Market
- Insiders
- Debra Stephanie Barker
